Over $1 Billion in Holdings... Gilead CEO Cashes Out Hundreds of Millions Through Stock Options

Gilead Sciences, Inc. (GILD) disclosed on February 10 that its Chairman and CEO, Daniel Patrick O’Day, had liquidated nearly $20 million in equity under a prearranged Rule 10b5-1 trading plan on January 28 and February 5, using both common stock and stock options. The transactions included the sale of roughly 10,000 existing common shares and the exercise of several hundred thousand stock options at $66.01 per share, followed by the sale of those shares at $150 each.

After these trades, O’Day still directly holds about 614,000 shares of Gilead common stock, representing an equity value of approximately $92 million (around KRW 1.2 trillion) based on the reported reference price.

On the same day, Gilead reported its fourth-quarter and full-year 2025 financial results: revenue of $7.9 billion (roughly KRW 10 trillion) for Q4 and $29.4 billion (about KRW 38 trillion) for the year, up 5% and 2% year-over-year, respectively. Growth in HIV therapies and the liver-disease portfolio largely offset a 49% decline in sales of its COVID-19 treatment, Veklury.

Earlier, Gilead had raised its first-quarter 2025 dividend by 2.6% to $0.79 per share. Strong fourth-quarter 2024 revenue and earnings, which exceeded market expectations, further underscored the momentum in its HIV treatment business.

Headquartered in Foster City, California, Gilead Sciences is a major biopharmaceutical company with a leading global position in antivirals, focusing on treatments for serious infectious diseases and oncology, including HIV, hepatitis B and C, influenza, COVID-19, and cancer.

Daniel O’Day has served as Gilead’s Chairman and CEO since March 2019. He brings over 30 years of experience in the global pharmaceutical and diagnostics industry, including a prior role as CEO of Roche Pharmaceuticals.